원문정보
초록
영어
Thiazolidinedione insulin sensitizing agent is oral diabetic medicine of glitazone class with a novel mechanism showing an activity of improving insulin resistance, notably different from previous drugs that stimulate insulin secretion such as sulfonylurea or biguanide and
α-glucosidase inhibitor. The mechanism of action of such glitazone class is to boost the response for insulin in the target tissues of insulin. The molecular target of glitazone class was reported to be the PPARγ and it elicits its pharmacological action by binding and activating
nuclear receptor PPARγ. CKD Research Institute developed lobeglitazone featuring greater hypoglycemic activity than rosiglitazone and strengthened lipid lowering activity that tends to be pointed out as a weakness for PPARγ–acting drugs. Lobeglitazone is evaluated as a
phramacokinetically appropriate drug in terms of high bioavailability and the availability of once a day administration regimen to enhance the convenience of patients, which represent necessary features for oral medications. Phase II clinical study of lobeglitazone showed efficacy and safety in human diabetic patients and it was commenced to Phase III clinical study recently.